Risk factors for breast cancer development in patients with borderline breast lesions: a retrospective analysis of our outpatient facility

Introduction: Women affected by benign or borderline lesions will undergo a follow-up which includes both regular, usually yearly, clinical examinations and imaging repetition. The present study aims to determine how many women with a previous diagnosis of breast lesion of uncertain significance develop breast cancer during follow-up and to assess their risk factors. Materials and Methods: This retrospective study included women followed up in the present surgical outpatient facility who underwent a diagnosis of breast lesion of uncertain malignant potential (classified equal or greater than B3 or equal or greater than C3) between January 2003 and June 2014. Main outcomes were the occurrence of breast cancer during follow up and the analysis of possible risk factors for breast cancer development. Results: Among 513 included women, 15 developed breast cancer during the follow up for a borderline breast lesion. The cumulative incidence of new breast cancer diagnosis among women with a previous histological or cytological diagnosis of breast lesion of uncertain malignant potential was 4.3% (95% CI, 1.9-6.6%) at seven years of follow up. Furthermore, the presence of atypical ductal hyperplasia (ADH) and lobular intraepithelial neoplasia (LIN) in the surgical excision specimen, as well as the coexistence of hypothyroidism, resulted to be significant risk factors for new breast cancer development among these patients. Conclusions: Due to the great heterogeneity of benign breast disease, further studies are required to better define its risk to evolve into breast cancer, and consequently to optimize their follow up and management in order to reduce over-treatment of low-risk patients, while improving breast cancer diagnosis among high-risk women.

Breast lesions of uncertain malignant potential; Breast cancer; Risk factors; Hypothyroidism; Predictive factors

[1] Cedolini C., Bertozzi S., Londero A.P., Bernardi S., Seriau L., Concina S., et al.: “Type of breast cancer diagnosis, screening, and survival”. Clin. Breast Cancer,. 2014, 14, 235.

[2] Driul L., Bernardi S., Bertozzi S., Schiavon M., Londero A.P., Petri R.: “New surgical trends in breast cancer treatment: conservative interventions and oncoplastic breast surgery”. Minerva Ginecol., 2013, 65, 289.

[3] Perry N., Broeders M., de Wolf C., Törnberg S., Holland R., von Karsa L., et al.: “European guidelines for quality assurance in breast cancer screening and diagnosis” 4th ed. Luxembourg: Office for Official Publications of the European Communities, 2006.

[4] Bernardi S., Londero A.P., Bertozzi S., Driul L., Marchesoni D., Petri R.: “Breast-feeding and benign breast disease”. J. Obstet. Gynaecol., 2012, 32, 58.

[5] Reefy S., Osman H., Chao C., Perry N., Mokbel K.: “Surgical excision for B3 breast lesions diagnosed by vacuum-assisted core biopsy”. Anticancer Res., 2010, 30, 2287.

[6] Londero A.P., Bernardi S., Bertozzi S., Angione V., Gentile G., Dri C., et al.: “Synchronous and metachronous breast malignancies: a cross-sectional retrospective study and review of the literature”. Biomed. Res. Int., 2014, 2014, 250727.

[7] Bernardi S., Bertozzi S., Londero A.P., Angione V., Petri R., Giacomuzzi F.: “Prevalence and risk factors of intraoperative identification failure of sentinel lymph nodes in patients affected by breast cancer”. Nucl. Med. Commun., 2013, 34, 664.

[8] Bernardi S., Bertozzi S., Londero A.P., Gentile G., Angione V., Petri R.: “Influence of surgical margins on the outcome of breast cancer patients: a retrospective analysis”. World J. Surg., 2014, 38, 2279.

[9] Cedolini C., Bertozzi S., Seriau L., Londero A.P., Concina S., Cattin F., et al.: “Eight-year experience with the intraoperative frozen section examination of sentinel lymph node biopsy for breast cancer in a North-Italian university center”. Int. J. Clin. Exp. Pathol., 2014, 7, 364.

[10] Bernardi S., Bertozzi S., Londero A.P., Giacomuzzi F., Angione V., Dri C., et al.: “Nine years of experience with the sentinel lymph node biopsy in a single Italian center: a retrospective analysis of 1,050 cases”. World J. Surg., 2012, 36, 714.

[11] Cedolini C., Bertozzi S., Seriau L., Londero A.P., Concina S., Moretti E., et al.: “Feasibility of concervative breast surgery and intraoperative radiation therapy for early breast cancer: a single-center, open, non-randomized, prospective pilot study”. Oncol. Rep., 2014, 31, 1539.

[12] Bernardi S., Bertozzi S., Londero A.P., Gentile G., Giacomuzzi F., Carbone A.: “Incidence and risk factors of the intraoperative localization failure of nonpalpable breast lesions by radio-guided occult lesion localization: a retrospective analysis of 579 cases”. World. J. Surg., 2012, 36, 1915.

[13] Goehring C., Morabia A.: “Epidemiology of benign breast disease, with special attention to histologic types”. Epidemiol. Rev., 1997, 19, 310.

[14] Liang J., Shang Y.: “Estrogen and cancer”. Annu. Rev. Physiol., 2013, 75, 225.

[15] Chlebowski R.T., Manson J.E., Anderson G.L., Cauley J.A., Aragaki A.K., Stefanick M.L., et al.: “Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study”. J. Natl. Cancer Inst., 2013, 105, 526.

[16] Kahlenborn C., Modugno F., Potter D.M., Severs W.B.: “Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis”. Mayo Clin. Proc., 2006, 81, 1290.

[17] Charlton B.M., Rich-Edwards J.W., Colditz G.A., Missmer S.A., Rosner B.A., Hankinson S.E., et al.: “Oral contraceptive use and mortality after 36 years of follow-up in the Nurses’ Health Study: prospective cohort study”. BMJ, 2014, 349, g6356.

[18] Zervoudis S., Iatrakis G., Tomara E., Bothou A., Papadopoulos G., Tsakiris G.: “Main controversies in breast cancer”. World J. Clin. Oncol., 2014, 5, 359.

[19] Feig S.A.: “Screening mammography benefit controversies: sorting the evidence”. Radiol. Clin. North Am., 2014, 52, 455.

[20] Houssami N., Abraham L.A., Onega T., Collins L.C., Sprague B.L., Hill D.A., et al.: “Accuracy of screening mammography in women with a history of lobular carcinoma in situ or atypical hyperplasia of the breast”. Breast Cancer Res. Treat., 2014, 145, 765.

[21] Cuneo K.C., Dash R.C., Wilke L.G., Horton J.K., Koontz B.F.: “Risk of invasive breast cancer and ductal carcinoma in situ in women with atypical papillary lesions of the breast”. Breast J., 2012, 18, 475.

[22] Garmendia Madariaga A., Santos Palacios S., Guillén-Grima F., Galofré J.C.: “The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis”. J. Clin. Endocrinol. Metab., 2014, 99, 923.

[23] De Sibio M.T., de Oliveira M., Moretto F.C.F., Olimpio R.M.C, Conde S.J., Luvizon A.C., et al.: “Triiodothyronine and breast cancer”. World J. Clin. Oncol., 2014, 5, 503.

[24] Hardefeldt P.J., Eslick G.D., Edirimanne S.: “Benign thyroid disease is associated with breast cancer: a meta-analysis”. Breast Cancer Res. Treat., 2012, 133, 1169.

[25] Kalache A., Vessey M.P., McPherson K.: “Thyroid disease and breast cancer: findings in a large case-control study”. Br. J. Surg., 1982, 69, 434.

[26] Goldman M.B.: “Thyroid diseases and breast cancer”. Epidemiol. Rev., 1990, 12, 16.

[27] Cristofanilli M., Yamamura Y., Kau S.W., Bevers T., Strom S., Patangan M., et al.: “Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma”. Cancer, 2005, 103, 1122.

[28] Kuijpens J.L.P., Nyklíctek I., Louwman M.W.J., Weetman T.A.P., Pop V.J.M., Coebergh J.W.W.: “Hypothyroidism might be related to breast cancer in post-menopausal women”. Thyroid, 2005, 15, 1253.

[29] Ditsch N., Liebhardt S., Von Koch F., Lenhard M., Vogeser M., Spitzweg C., et al.: “Thyroid function in breast cancer patients”. Anticancer Res., 2010, 30, 1713.

[30] Heywang-Köbrunner S.H., Nährig J., Hacker A., Sedlacek S., Höfler H.: “B3 Lesions: Radiological Assessment and Multi-Disciplinary Aspects”. Breast Care (Basel), 2010, 5, 209.